Vis enkel innførsel

dc.contributor.authorValeberg, Berit Taraldsen
dc.contributor.authorPedersen, Linda Margareth
dc.contributor.authorGirotto, Valentina
dc.contributor.authorChristensen, Vivi Lycke
dc.contributor.authorStubhaug, Audun
dc.date.accessioned2018-01-22T10:00:48Z
dc.date.accessioned2018-03-23T08:56:14Z
dc.date.available2018-01-22T10:00:48Z
dc.date.available2018-03-23T08:56:14Z
dc.date.issued2017
dc.identifier.citationValeberg BT, Pedersen LM, Girotto, Christensen VL, Stubhaug A. Validation of the Norwegian pain sensitivity questionnaire. Journal of Pain Research. 2017;10:1137-1142en
dc.identifier.issn1178-7090
dc.identifier.urihttps://hdl.handle.net/10642/5807
dc.description.abstractBackground and purpose: There is a large variation in people’s reactions to painful stimuli. Although some conditions are more painful, the variation between people is larger than the reaction to pain across conditions. Induced experimental pain is one way to assess some aspects of these differences in pain perception. Experimental nociceptive testing is time consuming and not always feasible in a clinical setting. In order to overcome the obstacles of assessing pain sensitivity using experimental stimulation, the Pain Sensitivity Questionnaire (PSQ) was developed. The purpose of this study is to validate the Norwegian version of the PSQ. Methods: Construct validity was examined through an exploratory principal component factor analysis with varimax rotation. Internal consistency was measured by Cronbach’s alpha reliability for subscales and the total PSQ. As confounding variables such as age and gender may contribute to the experience of pain, a regression analysis was performed with demographic variables and PSQ scores as independent variables and the experimental measures of pain as the dependent variable. Results: The factor analysis yielded at two factor solution, with an eigenvalue greater than one, explain 58% of the variance. Cronbach’s alpha for the PSQ was 0.92. In the regression analysis, only PSQ scores contributed to explain the experimental pain intensity and tolerance. Gender only influenced the experimental pain threshold, as men had statistically significant higher heat pain threshold than women. Conclusion: This study shows that PSQ is a valid and reliable questionnaire and might be a promising instrument for assessing pain sensitivity in Norwegian clinical settings. Further studies are needed to examine whether the PSQ can be used in clinical settings to predict postoperative pain and the development of chronic pain.en
dc.language.isoenen
dc.publisherDove Medical Pressen
dc.rights© 2017 Valeberg et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php)en
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0
dc.subjectExperimental painen
dc.subjectPain sensitivity questionnaireen
dc.subjectFactor analysisen
dc.subjectGenderen
dc.titleValidation of the Norwegian pain sensitivity questionnaireen
dc.typeJournal articleen
dc.typePeer revieweden
dc.date.updated2018-01-22T10:00:48Z
dc.description.versionpublishedVersionen
dc.identifier.doihttp://doi.org/10.2147/JPR.S129540
dc.identifier.cristin1486383
dc.source.journalJournal of Pain Research


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

© 2017 Valeberg et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work 
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php)
Med mindre annet er angitt, så er denne innførselen lisensiert som © 2017 Valeberg et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php)